[{"id":"ffa36ee9-c0da-420e-bc20-b503b2b0b217","acronym":"TBCRC 058","url":"https://clinicaltrials.gov/study/NCT06099769","created_at":"2023-10-25T19:14:04.278Z","updated_at":"2025-02-25T15:36:36.074Z","phase":"Phase 2","brief_title":"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer","source_id_and_acronym":"NCT06099769 - TBCRC 058","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • PD-L1 • AR","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • AR positive","tags":["HER-2 • PD-L1 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • capecitabine • Xtandi (enzalutamide) • Halaven (eribulin mesylate) • Korlym (mifepristone) • Mifeprex (mifepristone)"],"overall_status":"Recruiting","enrollment":" Enrollment 201","initiation":"Initiation: 10/18/2023","start_date":" 10/18/2023","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-01-20"},{"id":"578ed237-447e-411c-ac2e-ddd1c7129e54","acronym":"OATH","url":"https://clinicaltrials.gov/study/NCT04719273","created_at":"2024-03-13T13:34:11.049Z","updated_at":"2024-07-02T16:35:14.938Z","phase":"Phase 2","brief_title":"Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer","source_id_and_acronym":"NCT04719273 - OATH","lead_sponsor":"Thomas Jefferson University","biomarkers":" ER • PGR","pipe":" | ","alterations":" PGR expression","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole • Apristor (onapristone XR)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 01/28/2021","start_date":" 01/28/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-13"},{"id":"50be0dbf-09bd-4202-b9dc-9320f03f560b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02788981","created_at":"2021-01-18T13:40:57.897Z","updated_at":"2024-07-02T16:35:19.046Z","phase":"Phase 2","brief_title":"Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer","source_id_and_acronym":"NCT02788981","lead_sponsor":"University of Chicago","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • Korlym (mifepristone)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 03/28/2017","start_date":" 03/28/2017","primary_txt":" Primary completion: 12/21/2022","primary_completion_date":" 12/21/2022","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-02-16"},{"id":"b4c10c17-3ade-414a-a83c-474c0b3bacd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04872608","created_at":"2021-05-04T11:52:45.021Z","updated_at":"2024-07-02T16:35:49.411Z","phase":"Phase 1b","brief_title":"A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer","source_id_and_acronym":"NCT04872608","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • letrozole • Apristor (onapristone XR)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/09/2021","start_date":" 09/09/2021","primary_txt":" Primary completion: 04/25/2023","primary_completion_date":" 04/25/2023","study_txt":" Completion: 04/25/2023","study_completion_date":" 04/25/2023","last_update_posted":"2023-04-28"},{"id":"068e98ca-b609-443c-b617-92e17feb845f","acronym":"ELONA","url":"https://clinicaltrials.gov/study/NCT05618613","created_at":"2022-11-16T18:56:49.734Z","updated_at":"2024-07-02T16:35:52.141Z","phase":"Phase 1b","brief_title":"Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT05618613 - ELONA","lead_sponsor":"Context Therapeutics Inc.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orserdu (elacestrant) • Apristor (onapristone XR)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 12/02/2022","start_date":" 12/02/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2023-03-28"},{"id":"f26d04a5-ba02-44dc-93a7-e1a000a2c333","acronym":"","url":"https://clinicaltrials.gov/study/NCT02012296","created_at":"2021-01-18T09:11:50.301Z","updated_at":"2024-07-02T16:36:07.346Z","phase":"Phase 1/2","brief_title":"Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer","source_id_and_acronym":"NCT02012296","lead_sponsor":"University of Chicago","biomarkers":" AR • NR3C1","pipe":" | ","alterations":" AR expression","tags":["AR • NR3C1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • Mifeprex (mifepristone)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 12/13/2013","start_date":" 12/13/2013","primary_txt":" Primary completion: 06/10/2019","primary_completion_date":" 06/10/2019","study_txt":" Completion: 08/01/2020","study_completion_date":" 08/01/2020","last_update_posted":"2022-07-13"},{"id":"844b7833-31df-4dc1-b105-7c986ff7435e","acronym":"MIPRA","url":"https://clinicaltrials.gov/study/NCT02651844","created_at":"2021-01-19T11:33:52.495Z","updated_at":"2024-07-02T16:36:10.813Z","phase":"","brief_title":"Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B.","source_id_and_acronym":"NCT02651844 - MIPRA","lead_sponsor":"Hospital Provincial Magdalena V. de Martínez","biomarkers":" CCND1 • CD4 • CASP3","pipe":" | ","alterations":" PGR expression","tags":["CCND1 • CD4 • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mifeprex (mifepristone)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 10/31/2019","primary_completion_date":" 10/31/2019","study_txt":" Completion: 10/31/2019","study_completion_date":" 10/31/2019","last_update_posted":"2022-05-06"},{"id":"1e224f1e-e84d-4899-b75d-1b6cfb6c01ea","acronym":"ONAWA","url":"https://clinicaltrials.gov/study/NCT04142892","created_at":"2021-01-18T20:13:20.240Z","updated_at":"2024-07-02T16:36:14.253Z","phase":"Phase 1","brief_title":"Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer","source_id_and_acronym":"NCT04142892 - ONAWA","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" HER-2 • ER • CD24 • ALDH1A1","pipe":" | ","alterations":" ER positive • HER-2 negative • CD44 expression • PGR expression","tags":["HER-2 • ER • CD24 • ALDH1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • CD44 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Apristor (onapristone XR)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 04/30/2021","primary_completion_date":" 04/30/2021","study_txt":" Completion: 04/30/2021","study_completion_date":" 04/30/2021","last_update_posted":"2022-04-01"},{"id":"b1f8c808-9544-4c95-9d8a-b140967d7dee","acronym":"","url":"https://clinicaltrials.gov/study/NCT01898312","created_at":"2021-01-18T08:32:20.792Z","updated_at":"2024-07-02T16:36:18.323Z","phase":"Phase 2","brief_title":"BRCA1/2 and Effect of Mifepristone on the Breast","source_id_and_acronym":"NCT01898312","lead_sponsor":"Karolinska Institutet","biomarkers":" PGR • BRCA1 • BRCA2 • PTEN • BCL2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["PGR • BRCA1 • BRCA2 • PTEN • BCL2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mifeprex (mifepristone)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2013","start_date":" 09/01/2013","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2022-01-19"},{"id":"9c2e3fcc-0c2c-452d-b5c3-1b136e0e84cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05016349","created_at":"2021-08-23T12:52:57.566Z","updated_at":"2024-07-02T16:36:25.993Z","phase":"Phase 3","brief_title":"Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.","source_id_and_acronym":"NCT05016349","lead_sponsor":"Mahmoud Ramadan mohamed Elkazzaz","biomarkers":" KRT5","pipe":"","alterations":" ","tags":["KRT5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Vesanoid (tretinoin) • Epidiolex (cannabidiol) • Mifeprex (mifepristone)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2021-08-23"},{"id":"ffded269-68dc-4fa7-ba1d-7177e5f5c3b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01493310","created_at":"2021-01-18T06:15:16.354Z","updated_at":"2024-07-02T16:37:06.992Z","phase":"Phase 1","brief_title":"Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT01493310","lead_sponsor":"University of Chicago","biomarkers":" ER • PGR","pipe":"","alterations":" ","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • Mifeprex (mifepristone)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 11/01/2011","start_date":" 11/01/2011","primary_txt":" Primary completion: 05/01/2018","primary_completion_date":" 05/01/2018","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2018-09-12"},{"id":"25460b04-df4b-4d99-905c-8ccb1c4d5086","acronym":"","url":"https://clinicaltrials.gov/study/NCT02046421","created_at":"2021-01-18T09:24:06.698Z","updated_at":"2024-07-02T16:37:07.046Z","phase":"Phase 1","brief_title":"Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02046421","lead_sponsor":"University of Chicago","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HR positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HR positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • Mifeprex (mifepristone)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 05/01/2018","primary_completion_date":" 05/01/2018","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2018-09-11"},{"id":"c5f64fa9-138b-4dfe-a9fb-1c488c2cbb7f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02014337","created_at":"2021-01-18T09:12:42.369Z","updated_at":"2024-07-02T16:37:14.764Z","phase":"Phase 1","brief_title":"Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors","source_id_and_acronym":"NCT02014337","lead_sponsor":"Corcept Therapeutics","biomarkers":" HER-2 • PGR","pipe":"","alterations":" ","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • Korlym (mifepristone)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2018-01-17"}]